SCHEMBL5715022

SCHEMBL5715022

O=C(Oc1ccc(Cc2ccccn2)cc1)N1CCN(c2ccccn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.58
ALDH1A1 P00352 8/20 0.58
TSHR P16473 4/20 0.58
CYP3A4 P08684 4/20 0.58
CYP2C9 P11712 4/20 0.58
CYP1A2 P05177 3/20 0.58
CYP2C19 P33261 3/20 0.58
MAPK1 P28482 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HPGD P15428 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
HTT P42858 1/20 0.52
KDM4E B2RXH2 6/20 0.51
CYP2D6 P10635 1/20 0.51
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714432 0.89 HSD17B10 (0.48) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714999 0.89 HSD17B10 (0.47) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5715207 0.89 KDM4E (0.50) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714360 0.89 TRPA1 (0.52) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714653 0.89 HSD17B10 (0.53) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714769 0.89 HSD17B10 (0.53) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5715148 0.89 KDM4E (0.55) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714370 0.88 SMO (0.49) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714105 0.88 HSD17B10 (0.48) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9
SCHEMBL5714866 0.86 TRPV1 (0.53) HSD17B10ALDH1A1TSHRCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HSD17B10 285/4885ALDH1A1 1021/4885TSHR 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.